These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

311 related items for PubMed ID: 25744224

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Antibody persistence and booster response following MenACWY-CRM vaccination in children as assessed by two different assay methods.
    Klein NP, Block SL, Essink B, Barbi S, Smolenov I, Keshavan P.
    Vaccine; 2019 Jul 26; 37(32):4460-4467. PubMed ID: 31279564
    [Abstract] [Full Text] [Related]

  • 5. Antibody persistence and response to a booster dose of a quadrivalent conjugate vaccine for meningococcal disease in adolescents.
    Jacobson RM, Jackson LA, Reisinger K, Izu A, Odrljin T, Dull PM.
    Pediatr Infect Dis J; 2013 Apr 26; 32(4):e170-7. PubMed ID: 23114372
    [Abstract] [Full Text] [Related]

  • 6. Safety and immunogenicity of a booster dose of meningococcal (groups A, C, W, and Y) polysaccharide diphtheria toxoid conjugate vaccine.
    Robertson CA, Greenberg DP, Hedrick J, Pichichero M, Decker MD, Saunders M.
    Vaccine; 2016 Oct 17; 34(44):5273-5278. PubMed ID: 27642132
    [Abstract] [Full Text] [Related]

  • 7. Immunogenicity, Safety and Antibody Persistence of a Booster Dose of Quadrivalent Meningococcal ACWY-tetanus Toxoid Conjugate Vaccine Compared with Monovalent Meningococcal Serogroup C Vaccine Administered Four Years After Primary Vaccination Using the Same Vaccines.
    Vesikari T, Forsten A, Bianco V, Van der Wielen M, Miller JM.
    Pediatr Infect Dis J; 2015 Dec 17; 34(12):e298-307. PubMed ID: 26780033
    [Abstract] [Full Text] [Related]

  • 8. Adolescent meningococcal serogroup A, W and Y immune responses following immunization with quadrivalent meningococcal A, C, W and Y conjugate vaccine: Optimal age for vaccination.
    van Ravenhorst MB, van der Klis FRM, van Rooijen DM, Sanders EAM, Berbers GAM.
    Vaccine; 2017 Aug 24; 35(36):4753-4760. PubMed ID: 28647167
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. MenACWY-CRM conjugate vaccine booster dose given 4-6 years after priming: Results from a phase IIIb, multicenter, open label study in adolescents and adults.
    Tipton M, Daly W, Senders S, Block SL, Lattanzi M, Mzolo T, Barbi S, Pellegrini M, Keshavan P.
    Vaccine; 2019 Sep 30; 37(42):6171-6179. PubMed ID: 31495595
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Five-year Antibody Persistence and Booster Response to a Single Dose of Meningococcal A, C, W and Y Tetanus Toxoid Conjugate Vaccine in Adolescents and Young Adults: An Open, Randomized Trial.
    Baxter R, Baine Y, Kolhe D, Baccarini CI, Miller JM, Van der Wielen M.
    Pediatr Infect Dis J; 2015 Nov 30; 34(11):1236-43. PubMed ID: 26237742
    [Abstract] [Full Text] [Related]

  • 14. Long-term antibody persistence after a booster dose of quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine in healthy 5-year-old children.
    Vesikari T, Forsten A, Laudat F, Li P, Van Der Wielen M, Hezareh M, Perez JL, Webber C.
    Vaccine; 2020 May 08; 38(22):3902-3908. PubMed ID: 32284274
    [Abstract] [Full Text] [Related]

  • 15. Persistence of the immune response after MenACWY-CRM vaccination and response to a booster dose, in adolescents, children and infants.
    Baxter R, Keshavan P, Welsch JA, Han L, Smolenov I.
    Hum Vaccin Immunother; 2016 May 03; 12(5):1300-10. PubMed ID: 26829877
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate vaccine in infants.
    Perrett KP, Snape MD, Ford KJ, John TM, Yu LM, Langley JM, McNeil S, Dull PM, Ceddia F, Anemona A, Halperin SA, Dobson S, Pollard AJ.
    Pediatr Infect Dis J; 2009 Mar 03; 28(3):186-93. PubMed ID: 19209097
    [Abstract] [Full Text] [Related]

  • 18. Immunogenicity and safety of the quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) in splenectomized or hyposplenic children and adolescents: Results of a phase III, open, non-randomized study.
    Klein NP, Habanec T, Kosina P, Shah NR, Kolhe D, Miller JM, Hezareh M, Van der Wielen M.
    Vaccine; 2018 Apr 19; 36(17):2356-2363. PubMed ID: 29576307
    [Abstract] [Full Text] [Related]

  • 19. Phase III comparison of an investigational quadrivalent meningococcal conjugate vaccine with the licensed meningococcal ACWY conjugate vaccine in adolescents.
    Jackson LA, Baxter R, Reisinger K, Karsten A, Shah J, Bedell L, Dull PM, V59P13 Study Group.
    Clin Infect Dis; 2009 Jul 01; 49(1):e1-10. PubMed ID: 19476428
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.